Tulun Ozturk1, Sule Gok, Nalan Nese. 1. Department of Anaesthesiology and Reanimation, Celal Bayar University School of Medicine, Manisa, Turkey. ozturktulun@yahoo.com
Abstract
OBJECTIVES: The aim of this study was to investigate the effect of levosimendan on apoptosis and infarct size when administered before ischemia in an isolated rat heart model. DESIGN: An in vitro experimental study. SETTING: Animal laboratory. PARTICIPANTS: Isolated perfused rat heart preparation (n = 22). INTERVENTIONS: Perfusion with Krebs-Henseleit solution was performed for 30 minutes and then 0.1 micromol/L of levosimendan was added to the perfusion fluid for 10 minutes before global ischemia; the control hearts received no levosimendan. Hearts underwent global ischemia for 30 minutes and then were reperfused for 30 minutes before specimens were obtained for testing. MEASUREMENTS AND MAIN RESULTS: Infarct sizes were measured at the end of the reperfusion period and expressed as a percentage of the area at risk. Myocardial apoptosis was detected by using the terminal deoxynucleotidyl transferase-mediated dUTP nick end-labelling (TUNEL) method. Bcl-2 expression was determined to detect antiapoptotic activity. Infarct size was significantly less in the levosimendan group (26% +/- 3% v 40% +/- 4%, respectively; p = 0.009). Levosimendan significantly reduced the proportion of TUNEL-positive cardiomyocytes (3 +/- 1 v 20 +/- 4, respectively; p < 0.001) and increased Bcl-2 expression compared with control hearts (44% +/- 3% v 31% +/- 3%, respectively; p = 0.01). Recovery of left ventricular-developed pressure 30 minutes after reperfusion in ischemic hearts pretreated with levosimendan was significantly better than that of placebo-treated hearts (53% +/- 3% v 38% +/- 3% of baseline, respectively; p = 0.004). CONCLUSIONS: Levosimendan has a cardioprotective effect when administered before ischemia in ischemia-reperfusion injury. This effect may be useful in elective cardiac surgery for protecting myocytes from ischemia-reperfusion-induced apoptosis. Copyright 2010 Elsevier Inc. All rights reserved.
OBJECTIVES: The aim of this study was to investigate the effect of levosimendan on apoptosis and infarct size when administered before ischemia in an isolated rat heart model. DESIGN: An in vitro experimental study. SETTING: Animal laboratory. PARTICIPANTS: Isolated perfused rat heart preparation (n = 22). INTERVENTIONS: Perfusion with Krebs-Henseleit solution was performed for 30 minutes and then 0.1 micromol/L of levosimendan was added to the perfusion fluid for 10 minutes before global ischemia; the control hearts received no levosimendan. Hearts underwent global ischemia for 30 minutes and then were reperfused for 30 minutes before specimens were obtained for testing. MEASUREMENTS AND MAIN RESULTS:Infarct sizes were measured at the end of the reperfusion period and expressed as a percentage of the area at risk. Myocardial apoptosis was detected by using the terminal deoxynucleotidyl transferase-mediated dUTP nick end-labelling (TUNEL) method. Bcl-2 expression was determined to detect antiapoptotic activity. Infarct size was significantly less in the levosimendan group (26% +/- 3% v 40% +/- 4%, respectively; p = 0.009). Levosimendan significantly reduced the proportion of TUNEL-positive cardiomyocytes (3 +/- 1 v 20 +/- 4, respectively; p < 0.001) and increased Bcl-2 expression compared with control hearts (44% +/- 3% v 31% +/- 3%, respectively; p = 0.01). Recovery of left ventricular-developed pressure 30 minutes after reperfusion in ischemic hearts pretreated with levosimendan was significantly better than that of placebo-treated hearts (53% +/- 3% v 38% +/- 3% of baseline, respectively; p = 0.004). CONCLUSIONS:Levosimendan has a cardioprotective effect when administered before ischemia in ischemia-reperfusion injury. This effect may be useful in elective cardiac surgery for protecting myocytes from ischemia-reperfusion-induced apoptosis. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Markus Malmberg; Tommi Vähäsilta; Antti Saraste; Juha W Koskenvuo; Jussi P Pärkkä; Kari Leino; Timo Laitio; Christoffer Stark; Aira Heikkilä; Pekka Saukko; Timo Savunen Journal: Front Physiol Date: 2012-02-14 Impact factor: 4.566
Authors: Stefanie N Brunner; Nicolai V Bogert; Andreas A Schnitzbauer; Eva Juengel; Anton Moritz; Isabella Werner; Angela Kornberger; Andres Beiras-Fernandez Journal: PLoS One Date: 2017-11-16 Impact factor: 3.240